Veracyte completes Decipher acquisition for $600M

2020 01 16 22 39 3973 Dna Sequencing Genome 400

Veracyte has completed a $600 million cash deal to acquire Decipher Biosciences, expanding its position in the genomics-driven cancer diagnostics sector. Decipher Biosciences is now a subsidiary of Veracyte.

Tina Nova, PhD, who is the previous president and chief executive officer at Decipher, has been appointed general manager of urologic cancers at Veracyte. She will continue to oversee the company's San Diego operations, including a CLIA-certified and College of American Pathologists (CAP)-accredited laboratory.

Page 1 of 2
Next Page